Twice-Yearly Biologic Effective Against Nasal Polyps
(MedPage Today) — SAN DIEGO — Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed.
Twice-yearly injections cut total nasal polyps score by a mean of 0.7 more than…
